BACKGROUND: Childhood cancer survivors are at higher risk of morbidity and mortality from cardiovascular disease compared with the general population. METHODS: Eight thousand five hundred ninety-nine survivors (52% male) and 2,936 siblings (46% male) from the Childhood Cancer Survivor Study, a retrospectively ascertained, prospectively followed study of persons who survived 5 years after childhood cancer diagnosed from 1970 to 1986, were evaluated for body mass index of > or =30 kg/m(2) based on self-reported heights and weights and self-reported use of medications for hypertension, dyslipidemia, and impaired glucose metabolism. The presence of three or more of the above constituted Cardiovascular Risk Factor Cluster (CVRFC), a surrogate for Metabolic Syndrome. RESULTS: Survivors were more likely than siblings to take medications for hypertension [odds ratio (OR), 1.9; 95% confidence interval (95% CI), 1.6-2.2], dyslipidemia (OR, 1.6; 95% CI, 1.3-2.0) or diabetes (OR, 1.7; 95% CI, 1.2-2.3). Among these young adults (mean age of 32 years for survivors and 33 years for siblings), survivors were not more likely than siblings to be obese or have CVRFC. In a multivariable logistic regression analysis, factors associated with having CVRFC included older age at interview [> or =40 versus <30 years of age (OR, 8.2; 95% CI, 3.5-19.9)], exposure to total body irradiation (OR, 5.5; 95% CI, 1.5-15.8) or radiation to the chest and abdomen (OR, 2.3; 95% CI, 1.2-2.4), and physical inactivity (OR, 1.7; 95% CI, 1.1-2.6). CONCLUSIONS: Among adult survivors of pediatric cancer, older attained age, exposure to total body irradiation or abdominal plus chest radiation, and a sedentary life-style are associated with CVRFC.
BACKGROUND:Childhood cancer survivors are at higher risk of morbidity and mortality from cardiovascular disease compared with the general population. METHODS: Eight thousand five hundred ninety-nine survivors (52% male) and 2,936 siblings (46% male) from the Childhood Cancer Survivor Study, a retrospectively ascertained, prospectively followed study of persons who survived 5 years after childhood cancer diagnosed from 1970 to 1986, were evaluated for body mass index of > or =30 kg/m(2) based on self-reported heights and weights and self-reported use of medications for hypertension, dyslipidemia, and impaired glucose metabolism. The presence of three or more of the above constituted Cardiovascular Risk Factor Cluster (CVRFC), a surrogate for Metabolic Syndrome. RESULTS: Survivors were more likely than siblings to take medications for hypertension [odds ratio (OR), 1.9; 95% confidence interval (95% CI), 1.6-2.2], dyslipidemia (OR, 1.6; 95% CI, 1.3-2.0) or diabetes (OR, 1.7; 95% CI, 1.2-2.3). Among these young adults (mean age of 32 years for survivors and 33 years for siblings), survivors were not more likely than siblings to be obese or have CVRFC. In a multivariable logistic regression analysis, factors associated with having CVRFC included older age at interview [> or =40 versus <30 years of age (OR, 8.2; 95% CI, 3.5-19.9)], exposure to total body irradiation (OR, 5.5; 95% CI, 1.5-15.8) or radiation to the chest and abdomen (OR, 2.3; 95% CI, 1.2-2.4), and physical inactivity (OR, 1.7; 95% CI, 1.1-2.6). CONCLUSIONS: Among adult survivors of pediatric cancer, older attained age, exposure to total body irradiation or abdominal plus chest radiation, and a sedentary life-style are associated with CVRFC.
Authors: Katarina Link; Christian Moëll; Stanislaw Garwicz; Eva Cavallin-Ståhl; Jonas Björk; Ulf Thilén; Bo Ahrén; Eva Marie Erfurth Journal: J Clin Endocrinol Metab Date: 2004-10 Impact factor: 5.958
Authors: Denise M Boudreau; Janet R Daling; Kathleen E Malone; Jacqueline S Gardner; David K Blough; Susan R Heckbert Journal: Am J Epidemiol Date: 2004-02-01 Impact factor: 4.897
Authors: Kevin C Oeffinger; Ann C Mertens; Charles A Sklar; Yutaka Yasui; Thomas Fears; Marilyn Stovall; Terry A Vik; Peter D Inskip; Leslie L Robison Journal: J Clin Oncol Date: 2003-04-01 Impact factor: 50.717
Authors: James G Gurney; Kirsten K Ness; Marilyn Stovall; Suzanne Wolden; Judy A Punyko; Joseph P Neglia; Ann C Mertens; Roger J Packer; Leslie L Robison; Charles A Sklar Journal: J Clin Endocrinol Metab Date: 2003-10 Impact factor: 6.134
Authors: David C Landy; Tracie L Miller; Gabriela Lopez-Mitnik; Stuart R Lipsitz; Andrea S Hinkle; Louis S Constine; Carol A French; Amy M K Rovitelli; M Jacob Adams; Steven E Lipshultz Journal: Am Heart J Date: 2012-02 Impact factor: 4.749
Authors: Tracie L Miller; Stuart R Lipsitz; Gabriela Lopez-Mitnik; Andrea S Hinkle; Louis S Constine; M Jacob Adams; Carol French; Cynthia Proukou; Amy Rovitelli; Steven E Lipshultz Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-07-20 Impact factor: 4.254
Authors: Smita Bhatia; Saro H Armenian; Gregory T Armstrong; Eline van Dulmen-den Broeder; Michael M Hawkins; Leontien C M Kremer; Claudia E Kuehni; Jørgen H Olsen; Leslie L Robison; Melissa M Hudson Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Emily S Tonorezos; Melissa M Hudson; Angela B Edgar; Leontien C Kremer; Charles A Sklar; W Hamish B Wallace; Kevin C Oeffinger Journal: Lancet Diabetes Endocrinol Date: 2015-04-12 Impact factor: 32.069
Authors: Andrew B Smitherman; Danielle Mohabir; Tania M Wilkins; Julie Blatt; Hazel B Nichols; Stacie B Dusetzina Journal: J Pediatr Date: 2018-02-12 Impact factor: 4.406